Roche H1 Results: 6% Growth, Exchange-Rate Adjusted
Roche (OTCQX:RHHBY) reported first-half 2026 Group sales of CHF 30.4 billion, up 6% at constant…
Roche Gazyva/Gazyvaro Gets FDA Priority Review
Roche (OTCQX:RHHBY) reported that the US FDA granted Priority Review to its supplemental Biologics License…
Roche gets FDA Priority Review for Enspryng TED
Roche (OTCQX:RHHBY) received FDA Priority Review for a supplemental Biologics License Application for…
Roche wins FDA Priority Review for Tecentriq colon use
Roche (OTCQX:RHHBY) received FDA Priority Review for a supplemental Biologics License Application for…
Roche breast cancer pill gets FDA priority review
Roche (OTCQX:RHHBY) reported that the US FDA accepted, under Priority Review, its New…